secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-05-27T10:40:32+00:00
Accession:  0001104659-26-066575
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee secures up to $1.3B non-dilutive financing from Blackstone for zumilokibart
--------------------------------------------------------------------------------

- $100M upfront received; additional $100M upon Phase 3 enrollment, $200M on positive Phase 3 data.
- Up to $400M more at FDA approval ($150M at Apogee's option); total synthetic royalty up to $800M.
- Low-to-mid single digit tiered royalties for 15 years on worldwide net sales; no royalties above $8B.
- Up to $500M senior corporate debt available at mutual consent with Blackstone.
- Company removes cash runway guidance; combined with $1.3B current cash positions for self-sustainability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465926066575/0001104659-26-066575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465926066575/tm2615568d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-066575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer